What is the dosage and use of Delamanid/Delba?

The clinical application of Delamanid (Delamanid) in tuberculosis (MDR-TB) (MDR-TB) emphasizes dose individualization and standardization of treatment courses. The recommended dose for adult patients is 100 mg twice a day for 24 weeks, which is the current standard treatment plan. For pediatric and adolescent patients, different doses are stratified according to weight: 50 mg twice daily for patients weighing 30 to 50 kg; 100 mg twice daily for patients weighing 50 kg and above. This dose stratification not only takes into account differences in drug distribution and metabolism in patients with different weights, but also takes into account efficacy and safety.

Delamanid is usually administered using directly observed therapy (DOT), that is, medical staff supervise patients to take the drug on time and in the right amount. DOT mode ensures patient compliance, improves treatment success, and facilitates real-time monitoring of potential adverse events and efficacy responses. During the treatment process, delamanidol is used in combination with other anti-tuberculosis drugs to form a multi-target mechanism of action, which significantly improves the inhibitory effect on multi-drug-resistant tuberculosis and reduces the emergence of drug-resistant strains.

After treatment, although the 24-week course of treatment is completed, the patient still needs to continue to receive combined anti-tuberculosis treatment and complete the entire standard course of multi-drug-resistant tuberculosis treatment in accordance with World Health Organization guidelines. During this period, regular monitoring of hematological indicators, liver function and electrocardiogram is crucial, so that potential risks such as QT interval prolongation and hematological abnormalities can be detected in time. Medical staff will adjust the dose or course of treatment according to the patient's actual condition to ensure it is both safe and effective.

As an important oral drug for multi-drug-resistant tuberculosis, delamanid not only has clear indications and scientific dosage design, but also achieves a balance between therapeutic effect and safety throughDOT administration mode, combination drug strategy and individualized dose adjustment. Its domestic launch provides standardized and scientific treatment options for MDR-TB patients and provides strong support for the management, prevention and control of MDR-TB.

Reference: https://go.drugbank.com/drugs/DB11637